Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Taxes (2016 - 2025)

Ani Pharmaceuticals' Current Taxes history spans 12 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Current Taxes fell 77.04% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 77.04%, while the annual FY2025 figure was $1.3 million, 77.04% down from the prior year.
  • Current Taxes for Q4 2025 was $1.3 million at Ani Pharmaceuticals, down from $3.3 million in the prior quarter.
  • Across five years, Current Taxes topped out at $14.2 million in Q1 2025 and bottomed at $594000.0 in Q3 2023.
  • The 4-year median for Current Taxes is $4.6 million (2021), against an average of $6.0 million.
  • The largest YoY upside for Current Taxes was 24.43% in 2025 against a maximum downside of 77.04% in 2025.
  • A 4-year view of Current Taxes shows it stood at $3.7 million in 2021, then soared by 123.12% to $8.2 million in 2023, then tumbled by 31.14% to $5.6 million in 2024, then plummeted by 77.04% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Current Taxes are $1.3 million (Q4 2025), $3.3 million (Q2 2025), and $14.2 million (Q1 2025).